

Sarah Allegra

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/9542633/sarah-allegra-publications-by-year.pdf>

Version: 2024-04-28

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

50
papers

421
citations

12
h-index

18
g-index

51
ext. papers

525
ext. citations

4.4
avg, IF

3.23
L-index

#	Paper	IF	Citations
50	Colorectal cancer chemotherapy: can sex-specific disparities impact on drug toxicities?. <i>European Journal of Clinical Pharmacology</i> , 2022 , 1	2.8	0
49	The Influence of Sex, Gender, and Age on COVID-19 Data in the Piedmont Region (Northwest Italy): The Virus Prefers Men. <i>Life</i> , 2022 , 12, 643	3	1
48	Antifungal Drug Plasma Exposures: A Possible Contribution of Vitamin D-Related Gene Variants. <i>Pharmaceuticals</i> , 2022 , 15, 630	5.2	
47	Gender-specific side effects of chemotherapy in pancreatic cancer patients.. <i>Canadian Journal of Physiology and Pharmacology</i> , 2021 , 1-7	2.4	0
46	Sex Differences on Mitotane Concentration and Treatment Outcome in Patients with Adrenocortical Carcinoma. <i>Life</i> , 2021 , 11,	3	2
45	Pharmacological and clinical evaluation of deferasirox formulations for treatment tailoring. <i>Scientific Reports</i> , 2021 , 11, 12581	4.9	3
44	Effect of Gender and Age on Voriconazole Trough Concentrations in Italian Adult Patients. <i>European Journal of Drug Metabolism and Pharmacokinetics</i> , 2020 , 45, 405-412	2.7	1
43	NURR1 deficiency is associated to ADHD-like phenotypes in mice. <i>Translational Psychiatry</i> , 2019 , 9, 207	8.6	11
42	Pharmacokinetics (PK), Pharmacodynamics (PD) and Safety Comparison of Deferasirox Formulations for Treatment Tailoring. <i>Blood</i> , 2019 , 134, 3547-3547	2.2	
41	Different Underlying Mechanism Might Explain the Absence of a Significant Difference in Area Under the Concentration-Time Curve of Linezolid for Different ABCB1 Genotypes. <i>Therapeutic Drug Monitoring</i> , 2019 , 41, 254-255	3.2	
40	The effect of vitamin D pathway genes and deferasirox pharmacogenetics on liver iron in thalassaemia major patients. <i>Pharmacogenomics Journal</i> , 2019 , 19, 417-427	3.5	4
39	Pharmacogenetic of voriconazole antifungal agent in pediatric patients. <i>Pharmacogenomics</i> , 2018 , 19, 913-925	2.6	10
38	Effect of ABCC2 and ABCG2 Gene Polymorphisms and CSF-to-Serum Albumin Ratio on Ceftriaxone Plasma and Cerebrospinal Fluid Concentrations. <i>Journal of Clinical Pharmacology</i> , 2018 , 58, 1550-1556	2.9	6
37	Correlation between entecavir penetration in peripheral blood mononuclear cells and HBV DNA decay during treatment of HBeAg-negative chronic hepatitis B. <i>Antiviral Therapy</i> , 2018 , 23, 373-377	1.6	2
36	Effect of pharmacogenetic markers of vitamin D pathway on deferasirox pharmacokinetics in children. <i>Pharmacogenetics and Genomics</i> , 2018 , 28, 17-22	1.9	4
35	Precision medicine for HIV: where are we?. <i>Pharmacogenomics</i> , 2018 , 19, 145-165	2.6	9
34	Clinical relevance of deferasirox trough levels in thalassaemia patients. <i>Clinical and Experimental Pharmacology and Physiology</i> , 2018 , 45, 213-216	3	3

33	Role of CYP24A1, VDR and GC gene polymorphisms on deferasirox pharmacokinetics and clinical outcomes. <i>Pharmacogenomics Journal</i> , 2018 , 18, 506-515	3.5	5
32	Therapeutic drug monitoring of voriconazole for treatment and prophylaxis of invasive fungal infection in children. <i>British Journal of Clinical Pharmacology</i> , 2018 , 84, 197-203	3.8	23
31	Role of CYP1A1, ABCG2, CYP24A1 and VDR gene polymorphisms on the evaluation of cardiac iron overload in thalassaemia patients. <i>Pharmacogenetics and Genomics</i> , 2018 , 28, 199-206	1.9	1
30	A Common <i>mdr1</i> Gene Polymorphism is Associated With Changes in Linezolid Clearance. <i>Therapeutic Drug Monitoring</i> , 2018 , 40, 602-609	3.2	6
29	A simple UHPLC-PDA method with a fast dilute-and-shot sample preparation for the quantification of canrenone and its prodrug spironolactone in human urine samples. <i>Journal of Pharmacological and Toxicological Methods</i> , 2018 , 94, 29-35	1.7	3
28	Deferasirox pharmacokinetic evaluation in β thalassaemia paediatric patients. <i>Journal of Pharmacy and Pharmacology</i> , 2017 , 69, 525-528	4.8	4
27	Pharmacokinetics of linezolid in critically ill patients: impact of continuous venovenous haemofiltration. <i>International Journal of Antimicrobial Agents</i> , 2017 , 49, 784-785	14.3	5
26	Role of vitamin D pathway gene polymorphisms on rifampicin plasma and intracellular pharmacokinetics. <i>Pharmacogenomics</i> , 2017 , 18, 865-880	2.6	5
25	Deferasirox pharmacogenetic influence on pharmacokinetic, efficacy and toxicity in a cohort of pediatric patients. <i>Pharmacogenomics</i> , 2017 , 18, 539-554	2.6	10
24	Pharmacokinetic evaluation of oral itraconazole for antifungal prophylaxis in children. <i>Clinical and Experimental Pharmacology and Physiology</i> , 2017 , 44, 1083-1088	3	13
23	Circannual variation of mitotane and its metabolites plasma levels in patients with adrenocortical carcinoma. <i>Journal of Pharmacy and Pharmacology</i> , 2017 , 69, 1524-1530	4.8	6
22	Evaluation of Posaconazole Pharmacokinetics in Adult Patients with Invasive Fungal Infection. <i>Biomedicines</i> , 2017 , 5,	4.8	12
21	Pharmacogenomic influence on sepsis outcome in critically ill patients. <i>Infezioni in Medicina</i> , 2017 , 25, 45-49	3.6	3
20	Role of pharmacogenetics on deferasirox AUC and efficacy. <i>Pharmacogenomics</i> , 2016 , 17, 561-72	2.6	13
19	Ethambutol plasma and intracellular pharmacokinetics: A pharmacogenetic study. <i>International Journal of Pharmaceutics</i> , 2016 , 497, 287-92	6.5	9
18	Pharmacogenetics of ribavirin-induced anemia in HCV patients. <i>Pharmacogenomics</i> , 2016 , 17, 925-41	2.6	16
17	Deferasirox pharmacokinetics evaluation in a woman with hereditary haemochromatosis and heterozygous β thalassaemia. <i>Biomedicine and Pharmacotherapy</i> , 2016 , 84, 1510-1512	7.5	2
16	Efavirenz pharmacogenetics in a cohort of Italian patients. <i>International Journal of Antimicrobial Agents</i> , 2016 , 47, 117-23	14.3	21

15	Deferasirox AUC efficacy cutoff and role of pharmacogenetics. <i>European Journal of Clinical Pharmacology</i> , 2016 , 72, 1155-7	2.8	8
14	Deferasirox pharmacokinetic and toxicity correlation in β -thalassaemia major treatment. <i>Journal of Pharmacy and Pharmacology</i> , 2016 , 68, 1417-1421	4.8	9
13	UPLC-MS/MS method for the simultaneous quantification of anti-HBV nucleos(t)ides analogs: Entecavir, lamivudine, telbivudine and tenofovir in plasma of HBV infected patients. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , 2015 , 114, 127-32	3.5	24
12	Intracellular accumulation of boceprevir according to plasma concentrations and pharmacogenetics. <i>International Journal of Antimicrobial Agents</i> , 2015 , 45, 657-61	14.3	8
11	Role of IL28B genotyping in patients with hepatitis C virus-associated mixed cryoglobulinemia and response to PEG-IFN and ribavirin treatment. <i>Archives of Virology</i> , 2015 , 160, 2009-17	2.6	7
10	VDR gene polymorphisms impact on anemia at 2 weeks of anti-HCV therapy: a possible mechanism for early RBV-induced anemia. <i>Pharmacogenetics and Genomics</i> , 2015 , 25, 164-72	1.9	10
9	UPLC-MS/MS method with automated on-line SPE for the isomer-specific quantification of the first-generation anti-HCV protease inhibitors in peripheral blood mononuclear cells. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , 2015 , 115, 443-9	3.5	9
8	Role of pharmacogenetic in ribavirin outcome prediction and pharmacokinetics in an Italian cohort of HCV-1 and 4 patients. <i>Biomedicine and Pharmacotherapy</i> , 2015 , 69, 47-55	7.5	12
7	ABCB11 and ABCB1 gene polymorphisms impact on telaprevir pharmacokinetic at one month of therapy. <i>Biomedicine and Pharmacotherapy</i> , 2015 , 69, 63-9	7.5	12
6	Influence of single-nucleotide polymorphisms on deferasirox C trough levels and effectiveness. <i>Pharmacogenomics Journal</i> , 2015 , 15, 263-71	3.5	16
5	Vitamin D pathway gene variants and HCV-2/3 therapy outcomes. <i>Antiviral Therapy</i> , 2015 , 20, 335-41	1.6	17
4	Intracellular and Plasma Trough Concentration and Pharmacogenetics of Telaprevir. <i>Journal of Pharmacy and Pharmaceutical Sciences</i> , 2015 , 18, 171-6	3.4	8
3	Intracellular accumulation of atazanavir/ritonavir according to plasma concentrations and OATP1B1, ABCB1 and PXR genetic polymorphisms. <i>Journal of Antimicrobial Chemotherapy</i> , 2014 , 69, 3061-6	5.1	34
2	Role of IL28-B polymorphisms in the treatment of chronic hepatitis B HBeAg-negative patients with peginterferon. <i>Antiviral Research</i> , 2014 , 102, 35-43	10.8	25
1	Identification of naïve HVC-4 patients who may be treated with pegylated-interferon and ribavirin according to IL28B polymorphisms. <i>Antiviral Research</i> , 2014 , 106, 105-10	10.8	9